Plain-English translation of NCT05389423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a newer immunomodulatory drug, combined with standard chemotherapy drugs to treat non-Hodgkin lymphoma (a type of blood cancer) in people living with HIV. Researchers believe this medication may work better than existing treatments because it can boost the immune system in ways that are especially helpful for people with HIV. The trial will first test different doses to find the safest and most effective amount, then expand to enroll more patients at that dose.
People living with HIV have a much higher risk of developing certain lymphomas than the general population, even with modern HIV treatment. This medication may be particularly useful because it's designed to strengthen the immune system while also fighting cancer, and it may be especially effective against lymphomas that involve the brain or spinal fluid—which happen more often in people with HIV.
You likely qualify if…
You likely don't qualify if…
You would receive the study medication and chemotherapy drugs as part of treatment cycles, likely through infusions or pills taken regularly. The trial has two phases: first, doctors will test different doses of the medication in a small group to find the right amount, then expand to treat more patients at the optimal dose. You'll need to attend regular visits for blood tests, scans, and check-ups, take daily aspirin or another blood-clot prevention medication, commit to HIV treatment, and follow strict birth control requirements. The exact duration and number of visits will depend on how you respond to treatment.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States